Announcement: Aurelia Bioscience has been acquired by Charnwood Molecular.

Share this

Drug Discovery 2022 promises to provide a platform for the whole drug discovery community to meet at a free to attend, in-person event. ELRIG has partnered with; BPS, SLAS, and RSC to draw together an exciting and progressive 2-day event containing; cutting-edge advancements in screening, automation and high content imaging, and innovations in disease models, advances in cell and gene therapies, revolutions through partnerships, future perspectives in medicinal and green chemistry and finally creative thinking to deliver therapies to one of the most challenging diseases facing society; COPD.

Members of our biology department and business development team will be on hand at the exhibition booth to outline how Charnwood Molecular is the ideal partner for early drug discovery.

Senior Director of Biology, Gary Allenby will also be presenting on Tuesday 4 October at 4.15pm on the topic of 'Magnetic Electrospun Microfibre Scaffold Assemblies: Examples of their use for Cell-Based Screening Applications'.

It will cover the following:

In an effort to create a more physiological three-dimensional (3-D) environment for cell growth while maintaining the logistics of well plate screening for drug discovery purposes, we have develop a 3-D micro-scaffold platform from electrospun material used in conjunction with well plates for higher throughput screening. We have engineered electrospun material to form micro-scaffold islands of cells. Cells grow on, around and into the material, effectively “3-D in solution”.

The incorporation of iron nano-particles into the fibres results in micro-scaffold islands that can be physically manipulated using electro-magnetism. We will show data of exemplar assays using recombinant, primary and differentiated stem cell assays on micro-scaffolds, using this approach to examine a number of luminescence and fluorescence readouts in recombinant cell lines and have differentiated iPSC’s to cortical neurones on micro-scaffolds to characterise then use imaging as a readout.

Data suggests that this micro-scaffold approach may open new opportunities for recombinant cell based screening and differentiated stem cell assays using single and co-cultures in a well plate-based format more amenable to higher throughputs with little manual intervention.

Email us to arrange a time to speak with one of our team at this event.